<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Med Oral Patol Oral Cir Bucal</journal-id><journal-id journal-id-type="iso-abbrev">Med Oral Patol Oral Cir Bucal</journal-id><journal-id journal-id-type="publisher-id">Medicina Oral S.L.</journal-id><journal-title-group><journal-title>Medicina Oral, Patolog&#x000ed;a Oral y Cirug&#x000ed;a Bucal</journal-title></journal-title-group><issn pub-type="ppub">1698-4447</issn><issn pub-type="epub">1698-6946</issn><publisher><publisher-name>Medicina Oral S.L.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39864090</article-id><article-id pub-id-type="pmc">PMC11972651</article-id>
<article-id pub-id-type="publisher-id">26896</article-id><article-id pub-id-type="doi">10.4317/medoral.26896</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject><subj-group><subject>Oral Cancer and Potentially malignant disorders</subject></subj-group></subj-group></article-categories><title-group><article-title>Grading systems and perineural invasion in oral squamous cell carcinoma - a disease-specific survival analysis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>de Aquino</surname><given-names>Sibele Nascimento</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>de Souza</surname><given-names>Lucas Lacerda</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Alvarenga</surname><given-names>Daniel</given-names></name><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Bonan</surname><given-names>Paulo Rog&#x000e9;rio Ferreti</given-names></name><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Martins</surname><given-names>Helder Domiciano Dantas</given-names></name><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Verner</surname><given-names>Francielle Silvestre</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Lopes</surname><given-names>M&#x000e1;rcio Ajudarte</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Vargas</surname><given-names>Pablo Agustin</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib></contrib-group><aff id="A1"><label>1</label>Applied Health Sciences Post-Graduate Program, Federal University of Juiz de Fora, Governador Valadares, Minas Gerais, Brazil</aff><aff id="A2"><label>2</label>Department of Oral Diagnosis, Piracicaba Dental School, University of Campinas, Piracicaba, Brazil</aff><aff id="A3"><label>3</label>Department of Medicine, Federal University of Juiz de Fora, Governador Valadares, Minas Gerais, Brazil</aff><aff id="A4"><label>4</label>Post-Graduate Program in Dentistry, Federal University of Para&#x000ed;ba, Jo&#x000e3;o Pessoa, Brazil</aff><author-notes><corresp> Department of Oral Diagnosis, Piracicaba Dental School
University of Campinas, 901, Limeira Avenue
Postcode: 13414-903. Piracicaba-SP, Brazil
, E-mail: <email>sibele.aquino@ufjf.br</email></corresp></author-notes><pub-date pub-type="ppub"><month>3</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>26</day><month>1</month><year>2025</year></pub-date><volume>30</volume><issue>2</issue><fpage>e247</fpage><lpage>e255</lpage><history><date date-type="accepted"><day>7</day><month>1</month><year>2025</year></date><date date-type="received"><day>30</day><month>8</month><year>2024</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2025 Medicina Oral S.L.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/2.5/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Background </title><p> Oral squamous cell carcinoma (OSCC) is an aggressive cancer, with prognosis influenced by clinical variables as well grading systems and perineural invasion (PNI), which are associated to poorer outcomes, including higher rates of recurrence and metastasis. This study aims to evaluate OSCC using three grading systems and assess the impact of PNI and clinicopathologic parameters on patient survival.</p></sec><sec><title>Material and Methods </title><p> Eighty-one primary OSCC samples were analyzed. Histopathological evaluations were performed utilizing Malignancy Grading of the Deep Invasive Margins, WHO grading system, and the Histologic Risk Assessment. S-100 immunohistochemistry was used to detect PNI. Five-year disease-specific survival (DSS) curves were generated using the Kaplan-Meier method, and the Cox proportional hazards model analyzed prognostic significance.</p></sec><sec><title>Results </title><p> Advanced clinical stage was significantly associated with reduced survival (<italic>p-value</italic> &#x0003c;0.001, HR = 4.07). Patients without regional lymph node involvement had better survival (<italic>p-value</italic> 0.002, HR = 0.37). Higher histologic risk assessment scores were linked to worse outcomes. Multifocal neural invasion significantly correlated with poorer survival compared to unifocal invasion (<italic>p-value</italic> 0.017, HR = 4.20). Patients undergoing surgery followed by adjuvant therapies had better survival rates.</p></sec><sec><title>Conclusions </title><p> Besides clinical stage and histological grade, PNI also showed to be a crucial prognostic factor in OSCC, necessitating aggressive treatment strategies.</p><p><bold> Key words:</bold>Squamous cell carcinoma, histological grade, neural invasion, prognosis, outcome.</p></sec></abstract></article-meta></front><body><sec><title>Introduction</title><p>Oral squamous cell carcinoma (OSCC) is the most prevalent type of oral cancer, predominantly associated to chronic consumption of tobacco, alcohol, and betel nut, varying by geographical region (<xref rid="B1" ref-type="bibr">1</xref>). Surgery is the most common treatment modality, with radiation and/or chemotherapy often used as adjuvant therapy (<xref rid="B2" ref-type="bibr">2</xref>). Typically, treatment decisions are guided by the TNM classification system (<xref rid="B3" ref-type="bibr">3</xref>). However, even with identical treatment plans, patients at the same TNM stage can experience different outcomes. To address this variability, researchers have developed various histological grading systems to enhance the TNM staging system and improve the prediction of clinical outcomes, offering greater prognostic accuracy (<xref rid="B4" ref-type="bibr">4</xref>-<xref rid="B8" ref-type="bibr">8</xref>).</p><p>In 1920, Broders introduced a classification system for lip cancer, based on the resemblance of the neoplasm to normal squamous epithelium (<xref rid="B4" ref-type="bibr">4</xref>). The Multiparameter Grading System, established in 1986 by Anneroth <italic>et al</italic>., evaluated key histopathologic features such as keratinization, nuclear pleomorphism, mitotic activity, and the tumor-host relationship, including the pattern and depth of invasion and inflammatory infiltration (<xref rid="B5" ref-type="bibr">5</xref>). In 1992, Bryne <italic>et al</italic>. (<xref rid="B6" ref-type="bibr">6</xref>) proposed the Malignancy Grading of the Deep Invasive Margins for OSCC, focusing on the most invasive tumor cell front at the tumor-host interface.</p><p>The World Health Organization (WHO) revised its grading system in 2005 to categorize squamous cell carcinomas based on the degree of cell differentiation, dividing them into well-differentiated, moderately differentiated, and poorly differentiated tumors (<xref rid="B7" ref-type="bibr">7</xref>). Additionally, in 2005, Brandwein-Gensler <italic>et al</italic>. introduced the Histologic Risk Assessment, which evaluates the worst pattern of invasion, perineural invasion (PNI), and the lymphocytic response to tumors. This system assigns different scores for each feature, classifying patients into low-, intermediate-, and high-risk groups based on their likelihood of local recurrence and overall survival probability (<xref rid="B8" ref-type="bibr">8</xref>).</p><p>The evaluation of neural invasion was integrated into the grading system proposed by Brandwein-Gensler <italic>et al</italic>. (<xref rid="B8" ref-type="bibr">8</xref>) due to the neurotropic nature of OSCC, which can affect peripheral nerves in the head and neck region (<xref rid="B9" ref-type="bibr">9</xref>). PNI has been associated to adverse outcomes, including lymph node metastasis, locoregional recurrence, and poor overall, disease-free, and disease-specific survival (<xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B11" ref-type="bibr">11</xref>). In the Histologic Risk Assessment grading system, PNI is classified into three categories: none, involvement of small nerves (&#x0003c;1 mm), or involvement of large nerves (&#x0003e;1 mm), assigned scores of 0, 1, and 3, respectively (<xref rid="B12" ref-type="bibr">12</xref>). However, some researchers have argued that further subcategorization of neural involvement&#x02014;such as distinguishing between unifocal and multifocal, and between intratumoral and peripheral&#x02014;could improve prognostic predictions (<xref rid="B13" ref-type="bibr">13</xref>-<xref rid="B15" ref-type="bibr">15</xref>).</p><p>While the prognostic value of PNI is increasingly recognized (<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B15" ref-type="bibr">15</xref>), its effectiveness in prediction models that integrate other histopathological factors and grading systems remains underexplored. Therefore, the aim of this study was to examine the Malignancy Grading of the Deep Invasive Margins (<xref rid="B6" ref-type="bibr">6</xref>), the WHO grading system (<xref rid="B7" ref-type="bibr">7</xref>), and the Histologic Risk Assessment (<xref rid="B8" ref-type="bibr">8</xref>), along with the subcategorization of PNI in primary OSCC. This comprehensive approach seeks to understand their collective impact on prognostic factors and patient survival.</p></sec><sec><title>Material and Methods</title><p>- Study design</p><p>Cases diagnosed as OSCC were retrospectively from two Pathological Anatomy centres. Formalin-fixed paraffin-embedded (FFPE) tissue blocks were obtained, and new 4&#x003bc;m histological sections were cut and stained with hematoxylin and eosin (H&#x00026;E) for microscopic description and diagnostic confirmation following the 5th edition of the World Health Organization Classification of Head and Neck Tumors (<xref rid="B16" ref-type="bibr">16</xref>). We included patients who had only undergone surgical resections for previously untreated tumors. We excluded cases that lacked a complete clinical history or had insufficient tissue in the FFPE block. Cases diagnosed in the oropharyngeal region were also excluded.</p><p>The following information were extracted from the clinical records: patient sex, age at diagnosis, history of alcohol and/or tobacco consumption, tumor location, TNM classification according to the AJCC 8th edition (<xref rid="B17" ref-type="bibr">17</xref>), treatment (surgery alone or with radiotherapy and/or adjuvant chemotherapy), date of diagnosis, date of surgery, date and cause of death. Only patients with a minimum of 5 years of follow-up or who were deceased because of the disease were included.</p><p>- Histopathological analysis</p><p>Hematoxylin and eosin staining was conducted on all cases, and the slides were graded according to three established systems: the Malignancy Grading of the Deep Invasive Margins (<xref rid="B6" ref-type="bibr">6</xref>), the WHO grading system (<xref rid="B7" ref-type="bibr">7</xref>), and the Histologic Risk Assessment (<xref rid="B8" ref-type="bibr">8</xref>). For the Malignancy Grading of the Deep Invasive Margins, we assessed tumor cell characteristics such as the degree of keratinization, nuclear polymorphism, and the number of mitoses, as well as the tumor-host relationship, including the pattern and stage of invasion and lymphoplasmacytic infiltration. Each histopathologic feature was assigned a score from 1 to 4 (<xref rid="B6" ref-type="bibr">6</xref>), which were then summed to estimate the overall malignancy of the tumor. Using the WHO grading system, tumors were categorized into three levels of differentiation: well-differentiated, moderately differentiated, and poorly differentiated (<xref rid="B7" ref-type="bibr">7</xref>). The Histologic Risk Assessment involved evaluating lymphocytic infiltrate, the worst pattern of invasion, and perineural invasion (<xref rid="B8" ref-type="bibr">8</xref>). Based on these evaluations, tumors were further classified as Grade I, II, or III.</p><p>- Immunohistochemistry</p><p>Immunohistochemistry (IHC) was conducted on 3-&#x003bc;m-thick sections of formalin-fixed, paraffin-embedded tissue samples. Primary antibody targeting the S-100 protein (Dako, Carpinteria, CA, dilution 1:10000) was used to evaluate the presence of perineural invasion. The tissue sections were deparaffinized and hydrated before undergoing antigen retrieval, using either an EDTA/Tris solution (pH 9.0) or a citric acid solution (pH 6.0), as recommended by the manufacturer, for 15 minutes in an electric pressure cooker. Endogenous peroxidase activity was blocked with 6% hydrogen peroxide for 15 minutes. After this pretreatment, the sections were incubated with the primary antibody for 2 hours at room temperature. For detection, the Envision-Dual Link System-HRP (Dako, Carpinteria, CA) was applied according to the manufacturer&#x02019;s protocol, and staining was performed with diaminobenzidine (Dako, Carpinteria, CA) for 5 minutes. The sections were then counterstained with Carazzi&#x02019;s hematoxylin for 3 minutes. Positive controls were included, while negative controls were prepared by omitting the primary antibody.</p><p>The size of the largest involved nerve was classified as major or minor based on the diameter of the nerve bundle (greater or less than 1 mm, respectively) (<xref rid="B13" ref-type="bibr">13</xref>). The extent of perineural invasion (PNI) was recorded as unifocal or multifocal, depending on whether a single focus or multiple foci of PNI were observed, respectively (<xref rid="B14" ref-type="bibr">14</xref>).</p><p>- Statistical analysis</p><p>K-means clustering was employed to determine cutoff points for the categories, aiming to dichotomize them. The collected data were summarized using crosstabs, and associations between variables were evaluated using the chi-square test or Fisher's exact test. The focus of the survival analysis was on 5-year disease-specific survival (DSS), which is defined as the time between the date of diagnosis and the date of death due to OSCC. Survival curves were created using the Kaplan-Meier method and compared with the log-rank test. To identify independent risk factors associated with poor survival, the Cox proportional hazard model was used. Backward elimination was utilized to select the covariates included in the regression models. Data processing was carried out using JAMOVI (by the JAMOVI Project) software. The level of statistical significance was set at 5% (<italic>P</italic> &#x02264; 0.05).</p></sec><sec><title>Results</title><p>- Demographic characteristics</p><p>A total of 81 cases diagnosed as OSCC were retrieved from the assesses pathology files and included in the current study for analysis.</p><p><xref rid="T1" ref-type="table">Table 1</xref> presents the clinicopathologic features of the study cohort. Among the 81 patients included, 16 (19.75%) were under 50 years of age, while 65 (80.24%) were 50 years or older. The cohort consisted of 59 men (72.83%) and 22 women (27.16%). The primary tumor sites were the tongue in 38 patients (46.91%), the floor of the mouth in 19 patients (23.45%), the hard palate in 9 patients (11.1%), the buccal mucosa in 3 patients (3.70%), the retromolar region in 4 patients (4.93%), and multiple sites in 8 patients (9.87%). Smoking status showed that 17 patients were non-smokers (20.98%) and 52 were smokers (64.19%). Drinking status evidenced 29 individuals were never-Drinkers (35.80%), while 35 were drinkers (43.20%). Tumor stages were grouped into T1-2 (32 patients, 39.50%) and T3-4 (46 patients, 56.79%). Regional lymph node involvement was assessed, and 40 patients (49.38%) presented no lymph node involvement, while 38 patients (46.91%) showed regional lymph node involvement.</p><p>Tumor size revealed that 32 patients (39.5%) were in the early stages (<xref rid="B1" ref-type="bibr">1</xref>-<xref rid="B2" ref-type="bibr">2</xref>), while 46 (56.79%) were in the more advanced stages (<xref rid="B3" ref-type="bibr">3</xref>-<xref rid="B4" ref-type="bibr">4</xref>). Regional lymph node involvement was observed in 38 patients (46.91%), whereas 40 patients (49.38%) showed no lymph node involvement. Clinical stage showed 22 patients (27.16%) were classified as stages I-II, and 58 (71.60%) were classified as stages III-IV.</p><p>The treatment modalities varied among the patients. Radiotherapy was administered to 52 patients (64.19%), while 19 (23.45%) did not receive this model of treatment. Chemotherapy was used as treatment modality in 34 patients (41.97%), while in 33 patients (40.74%) it was not used. Additionally, 24 patients (29.62%) received a combination of surgery and either radiotherapy or chemotherapy.</p><p>- Histopathologic classification analysis</p><p>Histologic description</p><p>The histopathological assessment, based on Broders' classification and described by the WHO in 2005, showed no significant association with tumor size, lymph node metastasis, and clinical stage, similarly to the Malignancy Grading of Deep Invasive margins, described by Bryne <italic>et al</italic>. in 1992. When considering the histologic risk assessment described by Brandwein-Gensler in 2005, we found an association with tumor size (P-value: &#x02264;0.001) and clinical stage (P-value: &#x02264;0.001), and a tendency towards significance in lymph node metastasis (P-value: 0.05). In terms of neural invasion (as indicated by S100 expression), tumor size (P-value: 0.31) and lymph node metastasis (P-value: 0.73) did not show any significant results, but there was a significant result for clinical stage (P-value: &#x02264;0.006). When evaluating the foci of neural invasion, clinical stage evidenced significant result (P-value: 0.01). (<xref rid="T2" ref-type="table">Table 2</xref>).</p><p>- Survival Analysis</p><p>The univariate survival analysis showed that the absence of regional lymph node involvement was associated with improved survival (P-value: 0.002, HR = 0.37, 95% CI: 0.20-0.69) when compared to the presence of lymph node involvement. Clinical stage also demonstrated a significant relationship, with stages III-IV associated with reduced survival (P-value: 0.015, HR = 2.60, 95% CI: 1.20-5.59) relative to stages I-II. Furthermore, the analysis indicated that patients who did not undergo surgery with CT or RT had significantly reduced survival (P-value: 0.016, HR = 2.41, 95% CI: 1.18-4.93) compared to those who received these treatments.</p><p>
<fig position="float" id="F1"><label>Figure 1</label><caption><p>A - WHO/Broders (2005) (Well-differentiaded x moderately/poorly differentiated); B - Malignancy grading of deep invasive margins (&#x02264;8 points x &#x02265;9 points); C - Histologic risk assessment by Brandwein-Gensler <italic>et al</italic>. (2005) (&#x02264;2 points x &#x02265;3 points); D - Neural Invasion - Foci (unifocal x multifocal).</p></caption><graphic xlink:href="medoral-30-e247-g001" position="float"/></fig>
</p><p>
<fig position="float" id="F2"><label>Figure 2</label><caption><p>A-F: Photomicrographs of perineural invasion (PNI) (arrows) in OSCC, affecting nerves of different sizes as well multifocal involvement. A and B - PNI in different regions of the same tumor (H&#x00026;E, 10x). C- Presence of PNI in adjacent regions in the same tumor, involving minor nerve (H&#x00026;E, 10x). D - Same region as in photomicrographs C, with S100 staining (10x). E and F: Another case of multifocal PNI, involving a major nerve (H&#x00026;E and S100, 4x, respectively).</p></caption><graphic xlink:href="medoral-30-e247-g002" position="float"/></fig>
</p><p>The malignancy grading of deep invasive margins, as defined by Bryne <italic>et al</italic>. (1992), showed that patients with &#x02265;9 points had significantly reduced survival (P-value: 0.047, HR = 1.98, 95% CI: 1.01-3.90) compared to those with &#x02264;8 points. The histologic risk assessment by Brandwein-Gensler <italic>et al</italic>. (2005) revealed that patients with a score of &#x02265;3 points had significantly reduced survival (P-value: 0.001, HR = 3.26, 95% CI: 1.61-6.59) compared to those with 0-2 points. Additionally, multifocal neural invasion was associated with significantly reduced survival (P-value: 0.025, HR = 3.38, 95% CI: 1.16-9.83) compared to unifocal invasion (Fig. <xref rid="F1" ref-type="fig">1</xref>). Fig. <xref rid="F2" ref-type="fig">2</xref> illustrates the presence of PNI.</p><p>Radiotherapy approached statistical significance for patients not receiving it (P-value: 0.054, HR = 1.92, 95% CI: 0.99-3.73) compared to those receiving it. Chemotherapy did not demonstrate statistical significance, with patients not receiving it (P-value: 0.941, HR = 0.98, 95% CI: 0.52-1.84) compared to those who did. Lastly, the WHO - Broders (2005) classification approached statistical significance for moderately/poorly differentiated tumors (P-value: 0.071, HR = 1.70, 95% CI: 0.96-3.02) compared to well-differentiated tumors.</p><p>The multivariate analysis revealed that the presence of lymph node involvement was associated with significantly reduced survival (P-value &#x0003c;0.001, HR = 2.45, 95% CI: 1.89-5.97) compared to the absence of lymph node involvement. Clinical stage also had a significant impact, with stages III-IV associated with reduced survival (P-value &#x0003c;0.001, HR = 4.07, 95% CI: 1.21-13.63) relative to stages I-II. Furthermore, the analysis indicated that patients who did not undergo surgery with CT or RT had significantly reduced survival (P-value &#x0003c;0.001, HR = 2.72, 95% CI: 1.04-7.29) compared to those who received these treatments.</p><p>The Malignancy Grading of the Deep Invasive Margins by Bryne <italic>et al</italic>. (1992) did not show significant differences in survival, with a hazard ratio of 1.00 (P-value 1.0, 95% CI: 0.10-10.0) for patients with &#x02265;9 points compared to those with &#x02264;8 points. The Histologic Risk Assessment by Brandwein-Gensler <italic>et al</italic>. (2005) showed that patients with a score of &#x02265;3 points had a hazard ratio of 16.36 (P-value 0.761, 95% CI: 0.16-12.61), indicating no significant difference in survival compared to those with 0-2 points. Lastly, multifocal neural invasion was associated with reduced survival (P-value 0.017, HR = 4.20, 95% CI: 1.29-13.66) compared to unifocal invasion (<xref rid="T3" ref-type="table">Table 3</xref>).</p></sec><sec><title>Discussion</title><p>PNI is increasingly recognized as an important prognostic indicator in OSCC, suggesting a potential association with aggressive tumor behavior (<xref rid="B10" ref-type="bibr">10</xref>). PNI is associated with an increased likelihood of local and regional recurrence, as well as distant metastasis, which collectively contribute to poorer overall survival rates (<xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B18" ref-type="bibr">18</xref>). The presence of PNI in OSCC patients necessitates more aggressive treatment strategies, including adjuvant therapies such as radiotherapy or chemoradiotherapy (<xref rid="B19" ref-type="bibr">19</xref>). Our study corroborates these observations, demonstrating that multifocal neural invasion is significantly linked to reduced survival compared to unifocal invasion, thereby underscoring the prognostic importance of PNI in clinical practice (<xref rid="B20" ref-type="bibr">20</xref>).</p><p>The majority of patients in our study were aged 50 years or older, with a higher prevalence among males, aligning with demographic trends observed in OSCC (<xref rid="B21" ref-type="bibr">21</xref>). The tongue was identified as the most common primary tumor site, followed by the floor of the mouth, which reflects the high anatomical density of locoregional nerves in these areas (<xref rid="B19" ref-type="bibr">19</xref>-<xref rid="B21" ref-type="bibr">21</xref>). Smoking and alcohol consumption were prevalent lifestyle habits among the patients, both of which are known risk factors for OSCC development (<xref rid="B21" ref-type="bibr">21</xref>). Our findings revealed that a significant proportion of patients were diagnosed at advanced tumor stages (III and IV), with nearly half exhibiting regional lymph node involvement. These characteristics are well-documented predictors of poor prognosis in OSCC (<xref rid="B22" ref-type="bibr">22</xref>).</p><p>The data also demonstrated a significant association between advanced clinical stage and reduced survival, emphasizing the critical importance of early detection and comprehensive staging in improving patient outcomes (<xref rid="B22" ref-type="bibr">22</xref>,<xref rid="B23" ref-type="bibr">23</xref>). In addition, our study found that patients who underwent surgery followed by adjuvant radiotherapy or chemotherapy had better survival outcomes. This could be attributed to the comprehensive treatment approach required for patients with advanced disease stages, which necessitates both surgical intervention and adjuvant therapies to effectively manage the disease. This approach is supported by existing literature, which highlights the importance of combining surgery with additional treatments to improve prognosis in patients with advanced stages of the disease (<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B16" ref-type="bibr">16</xref>,<xref rid="B18" ref-type="bibr">18</xref>).</p><p>The histologic risk assessment by Brandwein-Gensler and colleagues has emerged as a significant predictor of survival in our study, with higher scores correlating with poorer outcomes. This finding underscores the importance of detailed histologic evaluations, including the assessment of PNI, in prognostication and treatment planning (<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B24" ref-type="bibr">24</xref>). Our results align with those reported by Brandwein-Gensler <italic>et al</italic>. (<xref rid="B8" ref-type="bibr">8</xref>), who also highlighted the adverse impact of PNI on survival. Specifically, multifocal neural invasion was identified as an independent prognostic factor, reinforcing the need for meticulous assessment of PNI during histopathological examination. Although the similarities with Brandwein-Gensler <italic>et al</italic>. (<xref rid="B8" ref-type="bibr">8</xref>), our study shows variations in sample size, cohort characteristics, and the specific variables included. While we aimed to align with Brandwein-Gensler&#x02019;s findings, the inherent differences in the patient populations, histopathological analysis and treatment protocols could explain why our results did not reach statistical significance in other variables in the multivariate analysis. In addition to the present result, our research evidenced multifocal PNI, which is consistent with previous studies that underscore the significance of PNI in OSCC, including the presence of multifocal invasion (<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B15" ref-type="bibr">15</xref>).</p><p>Moreover, research by Spoerl <italic>et al</italic>. (<xref rid="B10" ref-type="bibr">10</xref>) demonstrated that PNI correlates with increased cumulative and distant metastasis rates, further highlighting its role as an adverse prognostic feature. The inclusion of PNI in staging and risk assessments can significantly inform clinical decisions, particularly concerning the need for elective neck dissection and adjuvant therapies. These comprehensive evaluations and treatment strategies are critical in improving the management and outcomes of patients with OSCC (<xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B20" ref-type="bibr">20</xref>,<xref rid="B22" ref-type="bibr">22</xref>,<xref rid="B23" ref-type="bibr">23</xref>).</p></sec><sec><title>Conclusions</title><p>The histologic risk assessment by Brandwein-Gensler <italic>et al</italic>. has been validated as a predictor of survival, reinforcing the necessity for detailed histopathological evaluations, including meticulous PNI assessment. PNI is a critical prognostic indicator in OSCC, reflecting aggressive tumor behavior and associated with poorer overall survival rates due to increased local, regional, and distant recurrence. The need of incorporating adjuvant therapies such as radiotherapy or chemoradiotherapy in treatment strategies for patients with PNI is evident, as supported by our findings that multifocal neural invasion significantly reduces survival compared to unifocal invasion. This cohort emphasizes the importance of early detection and comprehensive staging to improve patient outcomes.</p></sec></body><back><ack><title>Acknowledgement</title><p>We acknowledge Minas Gerais State Research Foundation to support the present study (FAPEMIG/APQ 02833-18).</p></ack><sec><title>Funding</title><p>This study was financed by the Minas Gerais State Research Foundation (FAPEMIG/APQ 02833-18). </p></sec><sec sec-type="COI-statement"><title>Conflict of interest</title><p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
</p></sec><notes><title>Institutional Review Board Statement</title><p>This study was approved by the Ethics (protocol #1.821.102). All procedures adhered to the ethical standards set by the responsible committees on human experimentation, both at the institutional and national levels, and complied with the principles of the Helsinki Declaration of 1975, as revised in 2008.</p></notes><notes><title>Author Contributions</title><p> Conception and design: Sibele Nascimento de Aquino, Pablo Agustin Vargas
Administrative support: FADEPE - Foundation for Support and Development of Teaching, Research and Extension.
Collection and assembly of data: Daniel Alvarenga, Paulo Rog&#x000e9;rio Ferretti Bonan, and Helder Domiciano Dantas Martins.
Data analysis and interpretation: Sibele Nascimento de Aquino, Marcio Ajudarte Lopes, Alan Roger Santos-Silva.
Manuscript writing: Sibele Nascimento de Aquino and Lucas Lacerda de Souza
Final approval of manuscript: All authors.</p></notes><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badwelan</surname><given-names>M</given-names></name><name><surname>Muaddi</surname><given-names>H</given-names></name><name><surname>Ahmed</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>KT</given-names></name><name><surname>Tran</surname><given-names>SD</given-names></name></person-group><article-title>Oral Squamous Cell Carcinoma and Concomitant Primary Tumors, What Do We Know? A Review of the Literature</article-title><source>Curr Oncol</source><year>2023</year><volume>30</volume><fpage>3721</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">37185396</pub-id>
</element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>SH</given-names></name><name><surname>Hsiao</surname><given-names>SY</given-names></name><name><surname>Chang</surname><given-names>KY</given-names></name><name><surname>Chang</surname><given-names>JY</given-names></name></person-group><article-title>New Insights into Oral Squamous Cell Carcinoma: From Clinical Aspects to Molecular Tumorigenesis</article-title><source>Int J Mol Sci</source><year>2021</year><volume>22</volume><fpage>2252</fpage><pub-id pub-id-type="pmid">33668218</pub-id>
</element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Struckmeier</surname><given-names>AK</given-names></name><name><surname>Eichhorn</surname><given-names>P</given-names></name><name><surname>Agaimy</surname><given-names>A</given-names></name><name><surname>Buchbender</surname><given-names>M</given-names></name><name><surname>Moest</surname><given-names>T</given-names></name><name><surname>Lutz</surname><given-names>R</given-names></name></person-group><article-title>Comparison of the 7th and revised 8th UICC editions (2020) for oral squamous cell carcinoma: How does the reclassification impact staging and survival?</article-title><source>Virchows Arch</source><year>2024</year><volume>484</volume><fpage>901</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">38191928</pub-id>
</element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>NC</given-names></name><name><surname>Hsu</surname><given-names>JT</given-names></name><name><surname>Tsai</surname><given-names>KY</given-names></name></person-group><article-title>Survival and clinicopathological characteristics of different histological grades of oral cavity squamous cell carcinoma: A single-center retrospective study</article-title><source>PLoS One</source><year>2020</year><volume>15</volume><fpage>e0238103</fpage><pub-id pub-id-type="pmid">32841288</pub-id>
</element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anneroth</surname><given-names>G</given-names></name><name><surname>Batsakis</surname><given-names>J</given-names></name><name><surname>Luna</surname><given-names>M</given-names></name></person-group><article-title>Malignancy grading in oral squamous cell carcinoma in the floor of the mouth related to clinical evaluation</article-title><source>Scand J Dent Res</source><year>1986</year><volume>94</volume><fpage>347</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">3462898</pub-id>
</element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bryne</surname><given-names>M</given-names></name><name><surname>Koppang</surname><given-names>HS</given-names></name><name><surname>Lilleng</surname><given-names>R</given-names></name><name><surname>Kjaerheim</surname><given-names>A</given-names></name></person-group><article-title>Malignancy grading of the deep invasive margins of oral squamous cell carcinoma has high prognostic value</article-title><source>J Pathol</source><year>1992</year><volume>166</volume><fpage>375</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">1517891</pub-id>
</element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muller</surname><given-names>S</given-names></name><name><surname>Tilakaratne</surname><given-names>WM</given-names></name></person-group><article-title>Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Tumours of the Oral Cavity and Mobile Tongue</article-title><source>Head Neck Pathol</source><year>2022</year><volume>16</volume><fpage>54</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">35312982</pub-id>
</element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brandwein-Gensler</surname><given-names>M</given-names></name><name><surname>Teixeira</surname><given-names>MS</given-names></name><name><surname>Lewis</surname><given-names>CM</given-names></name><name><surname>Lee</surname><given-names>B</given-names></name><name><surname>Rolnitzky</surname><given-names>L</given-names></name><name><surname>Hille</surname><given-names>JJ</given-names></name></person-group><article-title>Oral squamous cell carcinoma: histologic risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival</article-title><source>Am J Surg Pathol</source><year>2005</year><volume>29</volume><fpage>167</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">15644773</pub-id>
</element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fagan</surname><given-names>JJ</given-names></name><name><surname>Collins</surname><given-names>B</given-names></name><name><surname>Barnes</surname><given-names>L</given-names></name><name><surname>D'Amico</surname><given-names>F</given-names></name><name><surname>Myers</surname><given-names>EN</given-names></name><name><surname>Johnson</surname><given-names>JT</given-names></name></person-group><article-title>Perineural invasion in squamous cell carcinoma of the head and neck</article-title><source>Arch Otolaryngol Head Neck Surg</source><year>1998</year><volume>124</volume><fpage>637</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">9639472</pub-id>
</element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spoerl</surname><given-names>S</given-names></name><name><surname>Spoerl</surname><given-names>S</given-names></name><name><surname>Reil</surname><given-names>S</given-names></name><name><surname>Gerken</surname><given-names>M</given-names></name><name><surname>Ludwig</surname><given-names>N</given-names></name><name><surname>Taxis</surname><given-names>J</given-names></name></person-group><article-title>Prognostic Value of Perineural Invasion on Survival and Recurrence in Oral Squamous Cell Carcinoma</article-title><source>Diagnostics (Basel)</source><year>2022</year><volume>12</volume><fpage>1062</fpage><pub-id pub-id-type="pmid">35626218</pub-id>
</element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dolens</surname><given-names>EDS</given-names></name><name><surname>Dourado</surname><given-names>MR</given-names></name><name><surname>Almangush</surname><given-names>A</given-names></name><name><surname>Salo</surname><given-names>TA</given-names></name><name><surname>Gurgel Rocha</surname><given-names>CA</given-names></name><name><surname>da Silva</surname><given-names>SD</given-names></name></person-group><article-title>The Impact of Histopathological Features on the Prognosis of Oral Squamous Cell Carcinoma: A Comprehensive Review and Meta-Analysis</article-title><source>Front Oncol</source><year>2021</year><volume>11</volume><fpage>784924</fpage><pub-id pub-id-type="pmid">34858861</pub-id>
</element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brandwein-Gensler</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>RV</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Penner</surname><given-names>C</given-names></name><name><surname>Theilken</surname><given-names>A</given-names></name><name><surname>Broughel</surname><given-names>D</given-names></name></person-group><article-title>Validation of the histologic risk model in a new cohort of patients with head and neck squamous cell carcinoma</article-title><source>Am J Surg Pathol</source><year>2010</year><volume>34</volume><fpage>677</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">20414102</pub-id>
</element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>ME</given-names></name><name><surname>Palla</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Elashoff</surname><given-names>DA</given-names></name><name><surname>Abemayor</surname><given-names>E</given-names></name><name><surname>St John</surname><given-names>MA</given-names></name></person-group><article-title>A novel classification system for perineural invasion in noncutaneous head and neck squamous cell carcinoma: histologic subcategories and patient outcomes</article-title><source>Am J Otolaryngol</source><year>2012</year><volume>33</volume><fpage>212</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">22177613</pub-id>
</element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aivazian</surname><given-names>K</given-names></name><name><surname>Ebrahimi</surname><given-names>A</given-names></name><name><surname>Low</surname><given-names>TH</given-names></name><name><surname>Gao</surname><given-names>K</given-names></name><name><surname>Clifford</surname><given-names>A</given-names></name><name><surname>Shannon</surname><given-names>K</given-names></name></person-group><article-title>Perineural invasion in oral squamous cell carcinoma: quantitative subcategorisation of perineural invasion and prognostication</article-title><source>J Surg Oncol</source><year>2015</year><volume>111</volume><fpage>352</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">25363330</pub-id>
</element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasmat</surname><given-names>S</given-names></name><name><surname>Ebrahimi</surname><given-names>A</given-names></name><name><surname>Gao</surname><given-names>K</given-names></name><name><surname>Low</surname><given-names>TH</given-names></name><name><surname>Palme</surname><given-names>C</given-names></name><name><surname>Gupta</surname><given-names>R</given-names></name></person-group><article-title>Multifocal perineural invasion is a better prognosticator than depth of invasion in oral squamous cell carcinoma</article-title><source>Head Neck</source><year>2019</year><volume>41</volume><fpage>3992</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">31487105</pub-id>
</element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muller</surname><given-names>S</given-names></name><name><surname>Tilakaratne</surname><given-names>WM</given-names></name></person-group><article-title>Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Tumours of the Oral Cavity and Mobile Tongue</article-title><source>Head Neck Pathol</source><year>2022</year><volume>16</volume><fpage>54</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">35312982</pub-id>
</element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lydiatt</surname><given-names>WM</given-names></name><name><surname>Patel</surname><given-names>SG</given-names></name><name><surname>O'Sullivan</surname><given-names>B</given-names></name><name><surname>Brandwein</surname><given-names>MS</given-names></name><name><surname>Ridge</surname><given-names>JA</given-names></name><name><surname>Migliacci</surname><given-names>JC</given-names></name></person-group><article-title>Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual</article-title><source>CA Cancer J Clin</source><year>2017</year><volume>67</volume><fpage>122</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">28128848</pub-id>
</element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Misztal</surname><given-names>CI</given-names></name><name><surname>Green</surname><given-names>C</given-names></name><name><surname>Mei</surname><given-names>C</given-names></name><name><surname>Bhatia</surname><given-names>R</given-names></name><name><surname>Velez Torres</surname><given-names>JM</given-names></name><name><surname>Kamrava</surname><given-names>B</given-names></name></person-group><article-title>Molecular and Cellular Mechanisms of Perineural Invasion in Oral Squamous Cell Carcinoma: Potential Targets for Therapeutic Intervention</article-title><source>Cancers (Basel)</source><year>2021</year><volume>13</volume><fpage>6011</fpage><pub-id pub-id-type="pmid">34885121</pub-id>
</element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cracchiolo</surname><given-names>JR</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Migliacci</surname><given-names>JC</given-names></name><name><surname>Katabi</surname><given-names>N</given-names></name><name><surname>Pfister</surname><given-names>DG</given-names></name><name><surname>Lee</surname><given-names>NY</given-names></name></person-group><article-title>Patterns of recurrence in oral tongue cancer with perineural invasion</article-title><source>Head Neck</source><year>2018</year><volume>40</volume><fpage>1287</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">29522275</pub-id>
</element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Binmadi</surname><given-names>N</given-names></name><name><surname>Alsharif</surname><given-names>M</given-names></name><name><surname>Almazrooa</surname><given-names>S</given-names></name><name><surname>Aljohani</surname><given-names>S</given-names></name><name><surname>Akeel</surname><given-names>S</given-names></name><name><surname>Osailan</surname><given-names>S</given-names></name></person-group><article-title>Perineural Invasion is a Significant Prognostic Factor in Oral Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis</article-title><source>Diagnostics (Basel)</source><year>2023</year><volume>13</volume><fpage>3339</fpage><pub-id pub-id-type="pmid">37958235</pub-id>
</element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>da Silva Souto</surname><given-names>AC</given-names></name><name><surname>Vieira Heimlich</surname><given-names>F</given-names></name><name><surname>Lima de Oliveira</surname><given-names>L</given-names></name><name><surname>Bergmann</surname><given-names>A</given-names></name><name><surname>Dias</surname><given-names>FL</given-names></name><name><surname>Sp&#x000ed;ndola Antunes</surname><given-names>H</given-names></name></person-group><article-title>Epidemiology of tongue squamous cell carcinoma: A retrospective cohort study</article-title><source>Oral Dis</source><year>2023</year><volume>29</volume><fpage>402</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">33964106</pub-id>
</element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voss</surname><given-names>JO</given-names></name><name><surname>Freund</surname><given-names>L</given-names></name><name><surname>Neumann</surname><given-names>F</given-names></name><name><surname>Mrosk</surname><given-names>F</given-names></name><name><surname>Rubarth</surname><given-names>K</given-names></name><name><surname>Kreutzer</surname><given-names>K</given-names></name></person-group><article-title>Prognostic value of lymph node involvement in oral squamous cell carcinoma</article-title><source>Clin Oral Investig</source><year>2022</year><volume>26</volume><fpage>6711</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">35895143</pub-id>
</element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nie</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>P</given-names></name><name><surname>Shang</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>B</given-names></name></person-group><article-title>Nomograms to predict the prognosis in locally advanced oral squamous cell carcinoma after curative resection</article-title><source>BMC Cancer</source><year>2021</year><volume>21</volume><fpage>372</fpage><pub-id pub-id-type="pmid">33827452</pub-id>
</element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahman</surname><given-names>N</given-names></name><name><surname>MacNeill</surname><given-names>M</given-names></name><name><surname>Wallace</surname><given-names>W</given-names></name><name><surname>Conn</surname><given-names>B</given-names></name></person-group><article-title>Reframing Histological Risk Assessment of Oral Squamous Cell Carcinoma in the Era of UICC 8th Edition TNM Staging</article-title><source>Head Neck Pathol</source><year>2021</year><volume>15</volume><fpage>202</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">32661668</pub-id>
</element-citation></ref></ref-list></back><floats-group><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Clinicopathologic findings of the analyzed cases.</p></caption><table frame="border" rules="all" width="100%"><thead><tr><th colspan="2" rowspan="1">Variable</th><th rowspan="1" colspan="1">N (%)</th></tr></thead><tbody><tr><td rowspan="2" align="center" valign="middle" colspan="1">Age</td><td align="center" valign="middle" rowspan="1" colspan="1"> &#x0003c; 50 years</td><td align="center" valign="middle" rowspan="1" colspan="1">16 (19.75)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"> &#x0003e; 50 years</td><td align="center" valign="middle" rowspan="1" colspan="1">65 (80.24)</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">Sex</td><td align="center" valign="middle" rowspan="1" colspan="1">Male</td><td align="center" valign="middle" rowspan="1" colspan="1">59 (72.83)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Female</td><td align="center" valign="middle" rowspan="1" colspan="1">22 (27.16)</td></tr><tr><td rowspan="6" align="center" valign="middle" colspan="1">Tumor site</td><td align="center" valign="middle" rowspan="1" colspan="1">Tongue</td><td align="center" valign="middle" rowspan="1" colspan="1">38 (46.91)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Floor of the mouth</td><td align="center" valign="middle" rowspan="1" colspan="1">19 (23.45)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hard palate</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (11.1)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Buccal mucosa</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (3.70)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Retromolar region</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (4.93)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Multiple site</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (9.87)</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">Smoking status</td><td align="center" valign="middle" rowspan="1" colspan="1">not Smoker</td><td align="center" valign="middle" rowspan="1" colspan="1">17 (20.98)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">smoker</td><td align="center" valign="middle" rowspan="1" colspan="1">52 (64.19)</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">Drinking status</td><td align="center" valign="middle" rowspan="1" colspan="1">never-Drinker</td><td align="center" valign="middle" rowspan="1" colspan="1">29 (35.80)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Drinker</td><td align="center" valign="middle" rowspan="1" colspan="1">35 (43.20)</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">Tumor size (T)</td><td align="center" valign="middle" rowspan="1" colspan="1">1-2</td><td align="center" valign="middle" rowspan="1" colspan="1">32 (39.50)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3-4</td><td align="center" valign="middle" rowspan="1" colspan="1">46 (56.79)</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">Regional lymph nodes (N)</td><td align="center" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">40 (49.38)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">38 (46.91)</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">Clinical Stage</td><td align="center" valign="middle" rowspan="1" colspan="1">I-II</td><td align="center" valign="middle" rowspan="1" colspan="1">22 (27.16)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">III-IV</td><td align="center" valign="middle" rowspan="1" colspan="1">58 (71.60)</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">Treatment - Radiotherapy (RT)</td><td align="center" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">19 (23.45)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">52 (64.19)</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">Treatment - Chemotherapy (CT)</td><td align="center" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">33 (40.74)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">34 (41.97)</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">Surgery + RT or CT</td><td align="center" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">48 (59.25)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">24 (29.62)</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">Outcome</td><td align="center" valign="middle" rowspan="1" colspan="1">Dead</td><td align="center" valign="middle" rowspan="1" colspan="1">45 (55.55)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Alive</td><td align="center" valign="middle" rowspan="1" colspan="1">36 (44.44)</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Analysis of the relationship between histological classifications/gradations and neural invasion with prognostic variables (T, nodal metastasis (N), and clinical stage). </p></caption><table frame="border" rules="all" width="100%"><thead><tr><th rowspan="2" colspan="3">Histopathological classification</th><th rowspan="2" colspan="1">N (%)</th><th rowspan="1" colspan="1">T</th><th rowspan="1" colspan="1">Nodal metastasis</th><th rowspan="1" colspan="1">Clinical Stage</th></tr><tr><th rowspan="1" colspan="1">
<italic>P-value</italic>
</th><th rowspan="1" colspan="1">
<italic>P-value</italic>
</th><th rowspan="1" colspan="1">
<italic>P-value</italic>
</th></tr></thead><tbody><tr><td rowspan="2" align="center" valign="middle" colspan="1">Broders' classification</td><td rowspan="2" align="center" valign="middle" colspan="1">WHO (2005)</td><td align="center" valign="middle" rowspan="1" colspan="1">Well-differentiated</td><td align="center" valign="middle" rowspan="1" colspan="1">43 (54.22)</td><td rowspan="2" align="center" valign="middle" colspan="1">0.77</td><td rowspan="2" align="center" valign="middle" colspan="1">0.07</td><td rowspan="2" align="center" valign="middle" colspan="1">0.14</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Moderately and poorly differentiated</td><td align="center" valign="middle" rowspan="1" colspan="1">36 (43.37)</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">Bryne et al.</td><td rowspan="2" align="center" valign="middle" colspan="1">Malignancy Grading of the Deep Invasive Margins (1992)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02264; 8 points</td><td align="center" valign="middle" rowspan="1" colspan="1">28 (33.73)</td><td rowspan="2" align="center" valign="middle" colspan="1">0.11</td><td rowspan="2" align="center" valign="middle" colspan="1">0.13</td><td rowspan="2" align="center" valign="middle" colspan="1">0.06</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x02265;9 points</td><td align="center" valign="middle" rowspan="1" colspan="1">53 (63.86)</td></tr><tr><td rowspan="8" colspan="1">Brandwein-Gensler et al.</td><td rowspan="2" align="center" valign="middle" colspan="1">Histologic Risk Assessment (2005)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02264;2 points</td><td align="center" valign="middle" rowspan="1" colspan="1">29 (34.94)</td><td rowspan="2" align="center" valign="middle" colspan="1">&#x02264;0.001 (0.30)*</td><td rowspan="2" align="center" valign="middle" colspan="1">0.05 (0.22)*</td><td rowspan="2" align="center" valign="middle" colspan="1">&#x02264;0.001 (0.34)*</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x02265;3 points</td><td align="center" valign="middle" rowspan="1" colspan="1">52 (62.63)</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">Neural Invasion - S100</td><td align="center" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">40 (50.63)</td><td rowspan="2" align="center" valign="middle" colspan="1">0.31</td><td rowspan="2" align="center" valign="middle" colspan="1">0.73</td><td rowspan="2" align="center" valign="middle" colspan="1">&#x02264;0.006 (0.31)*</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">39 (49.36)</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">Neural invasion - Foci</td><td align="center" valign="middle" rowspan="1" colspan="1">Unifocal</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (23.07)</td><td rowspan="2" align="center" valign="middle" colspan="1">0.44</td><td rowspan="2" align="center" valign="middle" colspan="1">0.70</td><td rowspan="2" align="center" valign="middle" colspan="1">0.01 (0.42)*</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Multifocal</td><td align="center" valign="middle" rowspan="1" colspan="1">30 (76.92)</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">Neural invasion - Size</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;1mm</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (17.94)</td><td rowspan="2" align="center" valign="middle" colspan="1">0.52</td><td rowspan="2" align="center" valign="middle" colspan="1">0.88</td><td rowspan="2" align="center" valign="middle" colspan="1">0.52</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;1mm</td><td align="center" valign="middle" rowspan="1" colspan="1">32 (82.05)</td></tr></tbody></table><table-wrap-foot><fn><p>* Cramer's V.
</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Univariate and multivariate analyses of survival in relation to clinicopathologic factors.</p></caption><table frame="border" rules="all" width="100%"><thead><tr><th rowspan="2" colspan="2">Variables</th><th rowspan="1" colspan="1">Univariate analysis</th><th rowspan="2" colspan="1">
<italic>P-value</italic>
</th><th rowspan="1" colspan="1">Multivariate analysis</th><th rowspan="2" colspan="1">
<italic>P-value</italic>
</th></tr><tr><th rowspan="1" colspan="1">HR (95% CI)</th><th rowspan="1" colspan="1">HR (95% CI)</th></tr></thead><tbody><tr><td rowspan="2" align="center" valign="middle" colspan="1">Age</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02264;50 years</td><td rowspan="2" align="center" valign="middle" colspan="1">1.12 (0.54-2.32)</td><td rowspan="2" align="center" valign="middle" colspan="1">0.761</td><td rowspan="2" align="center" valign="middle" colspan="1">-</td><td rowspan="2" align="center" valign="middle" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x02265;50 years</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">Sex</td><td align="center" valign="middle" rowspan="1" colspan="1">Male</td><td rowspan="2" align="center" valign="middle" colspan="1">0.76 (0.39-1.49)</td><td rowspan="2" align="center" valign="middle" colspan="1">0.425</td><td rowspan="2" align="center" valign="middle" colspan="1">-</td><td rowspan="2" align="center" valign="middle" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Female</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">Smoking status</td><td align="center" valign="middle" rowspan="1" colspan="1">Not Smoker</td><td rowspan="2" align="center" valign="middle" colspan="1">1.55 (0.78-3.07)</td><td rowspan="2" align="center" valign="middle" colspan="1">0.211</td><td rowspan="2" align="center" valign="middle" colspan="1">-</td><td rowspan="2" align="center" valign="middle" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Smoker</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">Drinking status</td><td align="center" valign="middle" rowspan="1" colspan="1">Never-drinker</td><td rowspan="2" align="center" valign="middle" colspan="1">1.35 (0.71-2.57)</td><td rowspan="2" align="center" valign="middle" colspan="1">0.365</td><td rowspan="2" align="center" valign="middle" colspan="1">-</td><td rowspan="2" align="center" valign="middle" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Drinker</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">Tumor (T)</td><td align="center" valign="middle" rowspan="1" colspan="1">1-2</td><td rowspan="2" align="center" valign="middle" colspan="1">1.49 (0.81-2.73)</td><td rowspan="2" align="center" valign="middle" colspan="1">0.197</td><td rowspan="2" align="center" valign="middle" colspan="1">-</td><td rowspan="2" align="center" valign="middle" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3-4</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">Regional lymph nodes (N)</td><td align="center" valign="middle" rowspan="1" colspan="1">No</td><td rowspan="2" align="center" valign="middle" colspan="1">0.37 (0.20-0.69)</td><td rowspan="2" align="center" valign="middle" colspan="1">0.002</td><td rowspan="2" align="center" valign="middle" colspan="1">2.45 (1.89-5.97)</td><td rowspan="2" align="center" valign="middle" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">Clinical Stage</td><td align="center" valign="middle" rowspan="1" colspan="1">I + II</td><td rowspan="2" align="center" valign="middle" colspan="1">2.60 1.20-5.59)</td><td rowspan="2" align="center" valign="middle" colspan="1">0.015</td><td rowspan="2" align="center" valign="middle" colspan="1">4.07 (1.21-13.63)</td><td rowspan="2" align="center" valign="middle" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">III + IV</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">Radiotherapy</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td rowspan="2" align="center" valign="middle" colspan="1">1.92 (0.99-3.73)</td><td rowspan="2" align="center" valign="middle" colspan="1">0.054</td><td rowspan="2" align="center" valign="middle" colspan="1">0.00 (0.00-0.01)</td><td rowspan="2" align="center" valign="middle" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">No</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">Chemotherapy</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td rowspan="2" align="center" valign="middle" colspan="1">0.98 (0.52-1.84)</td><td rowspan="2" align="center" valign="middle" colspan="1">0.941</td><td rowspan="2" align="center" valign="middle" colspan="1">-</td><td rowspan="2" align="center" valign="middle" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">No</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">Surgery with CT or RT</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td rowspan="2" align="center" valign="middle" colspan="1">2.41 (1.18-4.93)</td><td rowspan="2" align="center" valign="middle" colspan="1">0.016</td><td rowspan="2" align="center" valign="middle" colspan="1">2.72 (1.04-7.29)</td><td rowspan="2" align="center" valign="middle" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">No</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">WHO - Broders (2005)</td><td align="center" valign="middle" rowspan="1" colspan="1">Well-differentiated</td><td rowspan="2" align="center" valign="middle" colspan="1">1.70 (0.96-3.02)</td><td rowspan="2" align="center" valign="middle" colspan="1">0.071</td><td rowspan="2" align="center" valign="middle" colspan="1">1.00 (0.39-2.59)</td><td rowspan="2" align="center" valign="middle" colspan="1">0.996</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Moderately/poorly differenciated</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">Bryne et al., 1992
Malignancy Grading of the Deep Invasive Margins (1992)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02264;8 points</td><td rowspan="2" align="center" valign="middle" colspan="1">1.98 (1.01-3.90)</td><td rowspan="2" align="center" valign="middle" colspan="1">0.047</td><td rowspan="2" align="center" valign="middle" colspan="1">1.00 (0.10-10.0)</td><td rowspan="2" align="center" valign="middle" colspan="1">1.0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x02265;9 points</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">Brandwein-Gensler et al., 2005
Histologic Risk Assessment</td><td align="center" valign="middle" rowspan="1" colspan="1">0-2 points</td><td rowspan="2" align="center" valign="middle" colspan="1">3.26 (1.61-6.59)</td><td rowspan="2" align="center" valign="middle" colspan="1">0.001</td><td rowspan="2" align="center" valign="middle" colspan="1">16.36 (0.16-12.61)</td><td rowspan="2" align="center" valign="middle" colspan="1">0.761</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x02265;3 points</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">Neural invasion - Foci</td><td align="center" valign="middle" rowspan="1" colspan="1">Unifocal</td><td rowspan="2" align="center" valign="middle" colspan="1">3.38 (1.16-9.83)</td><td rowspan="2" align="center" valign="middle" colspan="1">0.025</td><td rowspan="2" align="center" valign="middle" colspan="1">4.20 (1.29-13.66)</td><td rowspan="2" align="center" valign="middle" colspan="1">0.017</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Multifocal</td></tr></tbody></table></table-wrap></floats-group></article>